Droperidol has comparable clinical efficacy against both nausea and vomiting

C. C. Apfel1*, O. S. Cakmakkaya2, G. Frings3, P. Kranke4, A. Malhotra1, A. Stader1, A. Turan5, A. Biedler6 and K. Kolodzie1

1Clinical Research Core, Department of Anesthesia and Perioperative Care, UCSF Mount Zion Hospital, University of California San Francisco, 1600 Divisadero Street, C-447, San Francisco, CA 94115, USA.
2Department of Anesthesiology and Reanimation, Cerrahpasa Medical School, University of Istanbul, Istanbul, Turkey.
3Department of Anesthesiology and Intensive Care, St Bernhard Hospital, Kamp-Lintfort, Germany.
4Department of Anesthesiology, University of Wuerzburg, Wuerzburg, Germany.
5Department of Outcomes Research, The Cleveland Clinic, OH, USA.
6Katholische Kliniken Essen Nord, Essen, Germany

*Corresponding author. E-mail: apfelc@anesthesia.ucsf.edu or apfel@ponv.org

Background. Droperidol is commonly noted to be more effective at preventing postoperative nausea (PON) than vomiting (POV) and it is assumed to have a short duration of action. This may be relevant for clinical decisions, especially for designing multiple-drug antiemetic regimens.

Methods. We conducted a post hoc analysis of a large multicentre trial. Within this trial, 1734 patients underwent inhalation anaesthesia and were randomly stratified to receive several antiemetic interventions according to a factorial design, one of which was droperidol 1.25 mg vs placebo. We considered differences to be significant when: (i) point estimates of one outcome are not within the limits of the confidence interval (CI) of the other outcome; and (ii) differences in risk ratio (also known as relative risks, RR) are at least 20%.

Results. Over 24 h, nausea was reduced from 42.9% in the control to 32.0% in the droperidol group, corresponding to a relative risk (RR) of 0.75 (95% CI from 0.66 to 0.84). Vomiting was reduced from 15.6% to 11.8%, and therefore associated with a similar RR of 0.76 (0.59–0.96).

In the early postoperative period (0–2 h), droperidol prevented nausea and vomiting similarly, with an RR of 0.57 (0.46–0.69) for nausea and 0.56 (0.37–0.85) for vomiting. In the late postoperative period (2–24 h), the RR was again similar with 0.83 (0.72–0.96) for nausea compared with 0.89 (0.66–1.18) for vomiting but significantly less compared with the early postoperative period.

Conclusions. We conclude that droperidol prevents PON and POV equally well, yet its duration of action is short-lived.


Keywords: anaesthesia, day-case; PONV

Accepted for publication: May 27, 2009

Despite considerable effort by anaesthetists, postoperative nausea and vomiting (PONV) occurs in one-quarter to one-third of surgical patients.1–4 The term PONV is used frequently in reports to describe both nausea and vomiting; however, the two responses are biologically distinct phenomena and should more appropriately be reported and analysed separately.5 6 Further evidence for this distinction can be found in a recent epidemiologic study by Stadler and colleagues7 who found that although most risk factors are predictive for both outcomes, some appear to be predictive for nausea only.8 It is thus conceivable that a drug used for the prevention of PONV may be, for example, more effective against nausea than vomiting.

Consistent with this notion, authors of a systematic review concluded that droperidol prevents nausea to a greater extent than vomiting,9 and this conclusion has
since been widely accepted. However, the conclusion of this systematic review is tempered by the fact that few studies separately report all relevant outcomes. Consequently, relative efficacies for nausea and vomiting were determined across different studies rather than strictly from studies that adequately evaluated both responses, making direct comparisons of the outcomes difficult.

We have previously designed and reported on an International Multicenter Protocol to assess the single and combined benefits of Antiemetic strategies in a Controlled clinical Trial of factorial design (IMPACT) that investigated the effect of six interventions on PONV. The data set of IMPACT allows us directly to analyse whether droperidol comparably reduces the relative risks (RRs) for nausea and for vomiting, or if there is a clinically relevant difference.

The minimal clinically significant difference (MCSD) is the smallest difference that clinicians and patients would care about. It is possible for the MCSD to be larger than the difference that could be detected as statistically significant in a given situation (especially a clinical trial involving a large population), in which case, a statistically, but not clinically, significant difference might be of little practical importance. For the purposes of this analysis, we considered differences to be clinically significant when: (i) point estimates of one outcome are not within the limits of the confidence interval (CI) of the other outcome; and (ii) risk ratios differences are at least 20%.

Methods

Protocol

The details of the underlying protocol for this post hoc analysis are described elsewhere. In brief, adult patients undergoing surgery under general anaesthesia met eligibility criteria, if they had at least two predictors of the simplified risk score for PONV, i.e. their calculated risk for PONV exceeded about 40%. The considered risk factors were: female gender, previous history of PONV, motion sickness, or both, non-smoking status, and the anticipated use of postoperative opioids.

With ethics committee approval and informed consent, participating patients were randomized to receive a combination of antiemetic interventions utilizing a factorial design. Therefore, all patients were randomized to ondansetron 4 mg vs placebo, dexamethasone 4 mg vs placebo, and droperidol 1.25 mg vs placebo.

Patients were monitored for nausea and vomiting for the first 24 h after surgery. The time, severity, and characteristics of any emetic episode were recorded on standardized forms. Patients who experienced postoperative nausea (PON), postoperative vomiting (POV), or both were considered having suffered PONV. Rescue antiemetic medication was provided in case of symptoms, upon active request, or both.

At 2 and 24 h after surgery, an investigator blinded to treatment recorded emetic episodes and the patient’s self-assessment of their strongest nausea during the preceding time interval using an 11-point verbal rating scale.

Results

Written informed consent was obtained from 1734 patients. The majority were females (81%), non-smokers (81%), and 34% had a positive history of PONV. Overall, 38% experienced nausea and 14% had at least one episode of vomiting within 24 h after surgery. Patient characteristics and the risk for PONV were similar between the two groups (Table 1).

For the overall 24 h period, PON was reduced from 42.9% in the placebo group to 32.0% in the droperidol group, corresponding to an RR of 0.75 (95% CI 0.66–0.84), or an RR reduction of 25% (Table 2). Vomiting was reduced from 15.6% in the placebo group to 11.8% in the droperidol group, corresponding to an RR of 0.76 (95% CI 0.59–0.96), or an RR reduction of 24% (Table 2). The RRs of 0.75 and 0.76 were clinically similar and CIs of nausea included the point estimate for vomiting and vice versa (Fig. 1).

During the first 2 h after surgery, droperidol prevented nausea and vomiting similarly, with an RR of 0.57 (0.46–0.69) for nausea and 0.56 (0.37–0.85) for vomiting (Table 2). During the late postoperative period (2–24 h), the RR was again similar with 0.83 (0.72–0.96) for nausea and 0.89 (0.66–1.18) for vomiting (Fig. 2).

Additionally, when comparing the efficacy of droperidol in the early (0–2 h) vs the late (2–24 h) postoperative period, the RR reduction decreases from 43% in the early
Discussion

In this analysis of a large, randomized, controlled, multicentre trial, the RR for nausea was 0.75 and for vomiting 0.81.13 However, these statements were based on the ratio of the absence of symptoms or the numbers needed to treat. Because both these measures are highly sensitive towards the baseline incidences, they do not allow a direct comparison of the efficacy for two outcomes with different incidences (i.e., nausea being more frequent than vomiting). In fact, when calculating the RRs for the symptoms based on that systematic review, the RR for overall nausea (0–24 h) was 0.76 (58% in the placebo group vs 45% in the droperidol group), and the RR for overall vomiting was 0.68 (46% vs 28%, Fig. 2). Thus, the RRs are again similar and we conclude that the data of that systematic review support our findings that droperidol reduces nausea and vomiting to a similar degree.

In the early postoperative period, the RRs for nausea and vomiting were 0.57 and 0.56, respectively. This is again similar to the data published in the systematic review where the RRs for nausea and vomiting were 0.48 (33% vs 16%) and 0.48 (29% vs 14%). Thus, the RRs for nausea and for vomiting are again similar. This was also the case when we compared the RRs for the late postoperative period of our data.

Another notable result of our analysis is the higher efficacy of droperidol to prevent PONV in early postoperative compared with the late postoperative period with RR of 0.57 vs 0.81 (Table 2, Fig. 3). This is consistent with the short half-life of droperidol of about 2 h and previous studies such as a paper from Australia where the RRs for nausea and vomiting were 0.57 and 0.56, respectively. This is again similar to the data published in the systematic review where the RRs for nausea and vomiting were 0.48 (33% vs 16%) and 0.48 (29% vs 14%). Thus, the RRs for nausea and vomiting are again similar. This was also the case when we compared the RRs for the late postoperative period of our data.

Table 1 Patients’ characteristics and calculated risk for PONV. Results presented as number of patients (%) or as mean (SD), as indicated. *The risk score is based on the four established predictors: female gender, non-smoking, history of PONV, and anticipated postoperative opioid requirements where each factor is counted as one point. Patients were eligible if at least two predictors were present. †Patients with 0–1 risk factors were anticipated to have at least two risk factors before randomization (e.g. no need for the anticipated postoperative opioids).

<p>| Table 2 RR, absolute risk reduction, and number-needed-to-treat. Results presented as number of patients (% of total) |
|--------------------------------------------------|-----------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Interval</th>
<th>Symptom</th>
<th>Control (n=867)</th>
<th>Droperidol (n=867)</th>
<th>Relative risk (95% CI)</th>
<th>P-value</th>
<th>Absolute risk reduction (%)</th>
<th>Number-needed-to-treat</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–2 h</td>
<td>Nausea</td>
<td>223 (25.7)</td>
<td>126 (14.5)</td>
<td>0.57 (0.46–0.69)</td>
<td>&lt;0.001</td>
<td>11.2</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>59 (6.8)</td>
<td>33 (3.8)</td>
<td>0.56 (0.37–0.85)</td>
<td>0.005</td>
<td>3</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Nausea, vomiting, or both</td>
<td>231 (26.6)</td>
<td>132 (15.2)</td>
<td>0.57 (0.47–0.69)</td>
<td>&lt;0.001</td>
<td>11.4</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Rescue treatment</td>
<td>31 (3.6)</td>
<td>6 (0.7)</td>
<td>0.19 (0.08–0.46)</td>
<td>&lt;0.001</td>
<td>2.9</td>
<td>35</td>
</tr>
<tr>
<td>2–24 h</td>
<td>Nausea</td>
<td>284 (32.8)</td>
<td>237 (27.4)</td>
<td>0.83 (0.72–0.96)</td>
<td>0.013</td>
<td>5.4</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>88 (10.2)</td>
<td>78 (9)</td>
<td>0.89 (0.66–1.18)</td>
<td>0.414</td>
<td>1.2</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td>Nausea, vomiting, or both</td>
<td>296 (34.2)</td>
<td>241 (27.8)</td>
<td>0.81 (0.71–0.94)</td>
<td>0.003</td>
<td>6.4</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Rescue treatment</td>
<td>18 (2.1)</td>
<td>17 (2.0)</td>
<td>0.94 (0.49–1.82)</td>
<td>0.86</td>
<td>0.1</td>
<td>867</td>
</tr>
<tr>
<td>0–24 h</td>
<td>Nausea</td>
<td>372 (42.9)</td>
<td>277 (32)</td>
<td>0.75 (0.66–0.84)</td>
<td>&lt;0.001</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>135 (15.6)</td>
<td>102 (11.8)</td>
<td>0.76 (0.59–0.96)</td>
<td>0.021</td>
<td>3.8</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Nausea, vomiting, or both</td>
<td>382 (44.1)</td>
<td>283 (32.6)</td>
<td>0.74 (0.66–0.84)</td>
<td>&lt;0.001</td>
<td>11.5</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Rescue treatment</td>
<td>47 (5.4)</td>
<td>21 (2.4)</td>
<td>0.45 (0.27–0.74)</td>
<td>0.001</td>
<td>3</td>
<td>33</td>
</tr>
</tbody>
</table>
Because of the short half-life, a longer antiemetic coverage may better be achieved through multiple recurrent small doses instead of one large bolus. This may be the reason why droperidol added to morphine in a patient-controlled analgesic pump has been shown by Tramer and colleagues to be highly effective in providing a full 24 h antiemetic coverage.

The results of our large multicentre trial suggest that droperidol reduces the risk for nausea and vomiting equally. The RR reductions for both symptoms were comparable. Therefore, for clinical practice and also for designing clinical trials with multiple antiemetic strategies, it is not necessary to consider anti-nauseous and anti-vomiting efficacies for droperidol separately. However, the antiemetic property of a single bolus is short-lived because of the short plasma half-life of droperidol.

Funding

This secondary analysis was supported by Dr Apfel’s discretionary funds for the Perioperative Clinical Research Core, Department of Anesthesia and Perioperative Care, UCSF.

The data collection of the original study was supported by: (a) the Department of Anaesthesiology, University of Würzburg, Grant 1518 TG 72, Würzburg, Germany, through grants from AstraZeneca, Hamburg, Germany; (b) Helsinki University Hospital, HUS-EVO Grants TYH 0324, TKK 2120, and TKK 3120, University of Helsinki, Helsinki, Finland; Biomedicum Helsinki Foundation, Finland; Finnish Medical Foundation, Helsinki, Finland; Maud Kuistila Foundation, Helsinki, Finland; Paulo Foundation, Espoo, Finland; and Research Foundation of Orion Corporation, Espoo, Finland.

References

Droperidol prevents nausea and vomiting equally

9 Apfel CC, Korttila K, Abdalla M, et al. An international multicenter protocol to assess the single and combined benefits of antiemetic interventions in a controlled clinical trial of a $2 \times 2 \times 2 \times 2 \times 2$ factorial design (IMPACT). Control Clin Trials 2003; 24: 736–51
11 Make B. How can we assess outcomes of clinical trials: the MCID approach. COPD 2007; 4: 191–4